Respiratory Devices: The world markets

Market Analysis

Clinica's in-depth report supplies you with vital strategic information on the current and future markets for respiratory devices in one easy-to-use source.

Respiratory Devices: The world markets provides international market coverage and investigates expanding sectors such as home healthcare. This report examines the latest developments in each key country market - showing you where the best business opportunities lie. Countries profiled include:

• US
• Japan
• Germany
• France
• UK
• Italy
• Spain

This report provides you with useful discussions on new product design, enabling you to assess which products are likely to succeed in this growing market. It details market size, forecasts to 2003, and market influencing factors for each of the following products:

diagnostic products

• spirometers
• peak flow devices
• plethysmographs
• ergometers

therapeutic products

• nebulisers
• humidifiers
• O2 therapy
• ventilators

Respiratory Devices: The world markets investigates the latest mergers and acquisitions of multinationals, as they attempt to access niche markets. The report provides you with 20 in-depth company profiles with sales figures, product information, company market shares and details of strategic alliances, joint ventures and agreements.

Companies profiled include: Aradigm; Boehringer Ingelheim; Chest MI Inc; Clement Clarke International Ltd; Dr�ger Group; Dura; Glaxo Wellcome; Erich Jaeger GmbH & Co; Infrasonics Inc; Invacare; Medical Industries America Inc; Micro Medical Ltd; Nellcor Puritan Bennett Incorporated; ResMed; Respironics Inc; Siemens AG; Spirometrics Medical Equipment Co; Sunrise Medical Inc; Vitalograph Ltd.

PUBLISHED: JUNE 1998
REF: CBS761E
PAGES: 231
PRICE: £445/$935/¥107,000

• Order this report.
• Request a catalogue.
• Home.

For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]

CONTENTS
LIST OF TABLES
LIST OF FIGURES
EXECUTIVE SUMMARY
ABBREVIATIONS

CHAPTER 1 INTRODUCTION
1.1 Aims of the report
1.2 Scope of the report
1.2.1 Products included
1.2.2 Countries included
1.2.3 Companies included
1.2.4 Years covered
1.3 Methodology
1.3.1 Trade data
1.3.2 Forecasting
1.3.3 GDP and GNP data
1.3.4 Currency exchange
1.4 Respiratory disorders
1.4.1 Asthma
1.4.2 Chronic obstructive pulmonary diseases
1.4.3 Sleep apnoea
1.4.4 Pulmonary infections and other conditions
1.5 Factors influencing respiratory disorders
1.5.1 Smoking
1.5.2 Pollution
1.5.3 AIDS
1.6 The respiratory industry

CHAPTER 2 THE GLOBAL MARKET OVERVIEW
2.1 Market values
2.2 Product shares
2.3 National shares

CHAPTER 3 PRODUCT OVERVIEW
3.1 Diagnostic equipment
3.1.1 Spirometers
3.1.2 PFMs
3.1.3 Whole-body PFTs
3.1.4 Bench apparatus
3.2 Therapeutic equipment
3.2.1 Inhaler devices
3.2.2 Humidifiers
3.2.3 O2-therapy equipment
3.2.4 CPAP equipment
3.2.5 Ventilators

CHAPTER 4 THE US MARKET
4.1 The US healthcare market
4.1.1 Population
4.1.2 Respiratory disorders
4.2 Other influencing factors
4.3 Healthcare reforms
4.4 The respiratory equipment market
4.4.1 The respiratory diagnostic equipment market
4.4.2 The respiratory therapeutic equipment market
4.5 Main trading partners

CHAPTER 5 THE JAPANESE MARKET
5.1 The Japanese healthcare market
5.1.1 Population
5.1.2 Respiratory disorders
5.2 Other influencing factors
5.3 Healthcare reforms
5.4 The respiratory equipment market
5.4.1 The respiratory diagnostic equipment market
5.4.2 The respiratory therapeutic equipment market
5.5 Main trading partners

CHAPTER 6 THE GERMAN MARKET
6.1 The German healthcare market
6.1.1 Population
6.1.2 Respiratory disorders
6.2 Other influencing factors
6.3 Healthcare reforms
6.4 The respiratory equipment market
6.4.1 The respiratory diagnostic equipment market
6.4.2 The respiratory therapeutic equipment market
6.5 Main trading partners

CHAPTER 7 THE FRENCH MARKET
7.1 The French healthcare market
7.1.1 Population
7.1.2 Respiratory disorders
7.2 Other influencing factors
7.3 Healthcare reforms
7.4 The respiratory equipment market
7.4.1 The respiratory diagnostic equipment market
7.4.2 The respiratory therapeutic equipment market
7.5 Main trading partners

CHAPTER 8 THE UK MARKET
8.1 The UK healthcare market
8.1.1 Population
8.1.2 Respiratory disorders
8.2 Other influencing factors
8.3 Healthcare reforms
8.4 The respiratory equipment market
8.4.1 The respiratory diagnostic equipment market
8.4.2 The respiratory therapeutic equipment market
8.5 Main trading partners

CHAPTER 9 THE ITALIAN MARKET
9.1 The Italian healthcare market
9.1.1 Population
9.1.2 Respiratory disorders
9.2 Other influencing factors
9.3 Healthcare reforms
9.4 The respiratory equipment market
9.4.1 The respiratory diagnostic equipment market
9.4.2 The respiratory therapeutic equipment market
9.5 Main trading partners

CHAPTER 10 THE SPANISH MARKET
10.1 The Spanish healthcare market
10.1.1 Population
10.1.2 Respiratory disorders
10.2 Other influencing factors
10.3 Healthcare reforms
10.4 The respiratory equipment market
10.4.1 The respiratory diagnostic equipment market
10.4.2 The respiratory therapeutic equipment market
10.5 Main trading partners

CHAPTER 11 RESPIRATORY EQUIPMENT COMPANIES
3M PHARMACEUTICALS
Company addresses
Respiratory equipment
Company finances
Strategies for success
ALLEGIANCE CORPORATION
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
ARADIGM CORPORATION
Company addresses
Respiratory equipment
Company finances
Strategies for success
ASTRA GROUP
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
BOEHRINGER INGELHEIM CORPORATION
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
CLEMENT CLARKE INTERNATIONAL
Company addresses
Respiratory equipment
Company finances
DR�GER GROUP
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
DURA PHARMACEUTICALS, INC
Company addresses
Respiratory equipment
Company finances
Strategies for success
GLAXO WELLCOME PLC
Company addresses
Respiratory equipment
Company finances
Strategies for success
INVACARE CORPORATION
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
MALLINCKRODT INCORPORATED
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
MICRO MEDICAL LIMITED
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
NOVAMETRIX MEDICAL SYSTEMS INCORPORATED
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
RESMED INCORPORATED
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
RESPIRONICS INCORPORATED
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
SIEMENS AKTIENGESELLSCHAFT
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
SMITHS INDUSTRIES
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
SUNRISE MEDICAL INCORPORATED
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
VITAL SIGNS INCORPORATED
Company addresses
Respiratory equipment
Company finances
Strategies for success
Market shares
VITALOGRAPH LIMITED
Company addresses
Respiratory equipment
Company finances
Strategies for success

CHAPTER 12 COMPANIES DIRECTORY
REFERENCES
APPENDIX 1 SITc 872.33
APPENDIX 2 EXCHANGE RATES

LIST OF TABLES
Table ES.1 Factors influencing the respiratory diagnostic and therapeutic device industries
Table ES.2 The top seven world markets for respiratory equipment (1998)
Table ES.3 Key respiratory equipment product types
Table 1.1 Respiratory equipment - the main products
Table 1.2 Total emissions of air pollutants*
Table 2.1 Estimated value of the global respiratory equipment market segments (1995-2003)*
Table 2.2 National shares of the global diagnostic equipment market (1998 and 2003)*
Table 2.3 National shares of the global therapeutic equipment market (1998 and 2003)*
Table 4.1 US population and predicted demographic development (1993-2020)*
Table 4.2 Deaths due to bronchitis, emphysema and asthma in the US (1990-1996)*
Table 4.3 Deaths due to respiratory disease by category in the US (1994-1996)
Table 4.4 Patients with respiratory diseases discharged from short stay hospitals in the US (1993-1995)*
Table 4.5 AIDS cases and deaths by year (1992-1997)
Table 4.6 The US GDP (1992-1997)*
Table 4.7 Value of the US respiratory diagnostic equipment market (1992-2003)*
Table 4.8 Value of US respiratory therapeutic equipment market (1992-2003)*
Table 5.1 Number of specialised chest units in Japan (1993)
Table 5.2 Japan's population and predicted demographic development (1993-2020)*
Table 5.3 Deaths due to bronchitis, emphysema and asthma in Japan (1989-1996)*
Table 5.4 Deaths due to bronchitis, emphysema and asthma in Japan (1993-1996)
Table 5.5 Japan's GDP (1992-1997)*
Table 5.6 Value of Japan's respiratory diagnostic equipment market (1992-2003)*
Table 5.7 Value of Japan's respiratory therapeutic equipment market (1992-2003)*
Table 6.1 Germany's population and predicted demographic development (1993-2020)*
Table 6.2 Deaths due to bronchitis, emphysema and asthma in Germany (1990-1993)
Table 6.3 German hospital discharges of patients diagnosed with bronchitis, emphysema and asthma (1993-1995)
Table 6.4 Germany's GDP (1992-1997)*
Table 6.5 Value of Germany's respiratory diagnostic equipment market (1992-2003)
Table 6.6 Value of Germany's respiratory therapeutic equipment market (1992-2003)*
Table 7.1 France's population and predicted demographic development (1993-2020)*
Table 7.2 Deaths due to bronchitis, emphysema and asthma in France (1990-1993)*
Table 7.3 France's GDP (1992-1997), expressed in billions
Table 7.4 Value of France's respiratory diagnostic equipment market (1992-2003)*
Table 7.5 Value of France's respiratory therapeutic equipment market (1992-2003)*
Table 8.1 The UK's population and predicted demographic development (1993-2020)*
Table 8.2 Deaths due to bronchitis, emphysema and asthma in the UK (1990-1993)*
Table 8.3 The UK's GDP (1992-1997), expressed in billions
Table 8.4 The UK government's expenditure on the NHS (1991-2003)
Table 8.5 Value of the UK's respiratory diagnostic equipment market (1992-2003)*
Table 8.6 Value of the UK's respiratory therapeutic equipment market (1992-2003)*
Table 9.1 Italy's population and predicted demographic development (1993-2020)*
Table 9.2 Deaths due to bronchitis, emphysema and asthma in Italy (1989-1994)
Table 9.3 Patients diagnosed with chronic bronchitis and asthma in Italy (1994)
Table 9.4 Italy's GDP (1992-1997), in US$ billion
Table 9.5 Value of Italy's respiratory diagnostic equipment market (1992-2003)*
Table 9.6 Value of Italy's respiratory therapeutic equipment market (1992-2003)*
Table 10.1 Spain's population and predicted demographic development (1993-2020)*
Table 10.2 Deaths due to bronchitis, emphysema and asthma in Spain (1989-1994)
Table 10.3 Spanish hospital discharges of patients diagnosed with bronchitis, emphysema and asthma (1994)
Table 10.4 Spain's GDP (1992-1997)
Table 10.5 Estimated value of Spain's respiratory diagnostic equipment market (1992-2003)*
Table 10.6 Value of Spain's respiratory therapeutic equipment market (1992-2003)*
Table 11.1 3M's sales (1993-1997), expressed in US$ million
Table 11.2 3M's regional results, as percentages of the total (1993-1997)
Table 11.3 3M's R&D expenditure (1993-1996), expressed in US$ million
Table 11.4 3M's estimated market shares (1998)
Table 11.5 Allegiance's net revenue and net income (1993-1997), expressed in US$ million
Table 11.6 Allegiance's R&D expenditure (1995-1997), expressed in US$ million
Table 11.7 Aradigm's net revenue and net income (1993-1997), expressed in US$ million
Table 11.8 Aradigm's R&D expenditure (1993-1997), expressed in US$ million
Table 11.9 Astra's total sales and net income (1993-1997), expressed in SKr million
Table 11.10 Astra's regional sales (1995-1997)
Table 11.11 Astra's R&D expenditure (1993-1997), expressed in SKr million
Table 11.12 Boehringer Ingelheim's net sales and net income (1993-1996)
Table 11.13 Boehringer Ingelheim's regional results (1995-1996), expressed in DM million
Table 11.14 Boehringer Ingelheim's R&D expenditure (1993-1996), expressed in US$ million
Table 11.15 Clement Clarke's turnover and operating profit (1993, 1995 and 1996)
Table 11.16 Clement Clarke's regional turnover (1993, 1995 and 1996)
Table 11.17 Clement Clarke's R&D expenditure (1993-1996), expressed in US$
Table 11.18 Dr�ger's net sales and net income (1993-1996), expressed in US$ million
Table 11.19 Dr�ger's net regional sales (1993-1996), expressed in millions
Table 11.20 Dura's net revenue and net income (1993-1997), expressed in US$ million
Table 11.21 Spiros Corp II's proposed expenditure (1998-2000), expressed in US$ million
Table 11.22 Glaxo Wellcome's sales and pre-tax profit (1995-1997), expressed in US$ million
Table 11.23 Glaxo Wellcome's regional results, as percentages of the total (1996-1997)
Table 11.24 Glaxo Wellcome's R&D expenditure (1995-1997), expressed in US$ million
Table 11.25 Invacare's net sales, gross profit and net earnings (1993-1997), expressed in US$ million
Table 11.26 Invacare's regional results, as a percentage of net revenue (1994-1996)
Table 11.27 Invacare's R&D expenditure (1993-1996), expressed in US$ million
Table 11.28 Mallinckrodt's net sales and earnings (1993-1997), expressed in US$ million
Table 11.29 Mallinckrodt's regional gross sales (1995-1997), expressed in US$ million
Table 11.30 Mallinckrodt's R&D expenditure (1995-1997), expressed in US$ million
Table 11.31 Mallinckrodt's estimated market shares (1998)
Table 11.32 Micro Medical's sales (1993-1997), expressed in millions
Table 11.33 Micro Medical's net regional sales (1993-1997)
Table 11.34 Novametrix's net revenue and net income (1993-1997), expressed in US$ million
Table 11.35 Novametrix's R&D expenditure (1993-1997), expressed in US$ million
Table 11.36 ResMed's net revenue and net income (1993-1997), expressed in US$ million
Table 11.37 ResMed's regional results, as a percentage of net revenue (1993-1997)
Table 11.38 ResMed's R&D expenditure (1993-1997), expressed in US$ million
Table 11.39 ResMed's estimated market shares (1998)
Table 11.40 Respironics' net revenue and net income (1993-1997), expressed in US$ million
Table 11.41 Respironics' net regional sales*, as a percentage of total net sales (1995-1997)
Table 11.42 Respironics' R&D expenditure (1995-1997), expressed in US$ million
Table 11.43 Siemens' net revenue and net income (1993-1997), expressed in US$ million
Table 11.44 Contribution of Siemens Medical System's sales to total net sales*
Table 11.45 Siemens' net regional sales, as a percentage of total net sales (1995-1997), expressed in US$ million
Table 11.46 Siemens' R&D expenditure (1993-1997), expressed in US$ million
Table 11.47 Siemens' estimated market shares (1998)
Table 11.48 SIMS' turnover and profit (1993-1997), expressed in US$ million
Table 11.49 Smiths Industries' regional results, as a percentage of net revenue (1996-1997)
Table 11.50 Sunrise Medical's net revenue and net income (1993-1997), expressed in US$ million
Table 11.51 Sunrise Medical's net regional sales, as a percentage of total net sales (1993-1997), expressed in US$ million
Table 11.52 Sunrise Medical's R&D expenditure (1993-1997), expressed in US$ million
Table 11.53 DeVilbiss' estimated market shares (1998)
Table 11.54 Vital Signs' product line contribution to total net sales (1993-1997), expressed in US$ million
Table 11.55 Vital Signs' net sales and net income (1993-1997), expressed in US$ million
Table 11.56 Vital Signs' R&D expenditure (1995-1997), expressed in US$ million
Table 11.57 Vitalograph's sales (1993-1997)
Table 11.58 Vitalograph's regional results, as percentages of the total (1993-1997)
Table 11.59 Vitalograph's R&D expenditure (1998-2000), expressed in US$ million
Table 11.60 Vitalograph's estimated market shares (1998)

Table A.1 Devices covered by the SITC 872.33

Table A.2 Exchange rates used in this report

LIST OF FIGURES
Figure ES.1 The top seven markets for respiratory equipment as percentages of the global market (1998)
Figure ES.2 Estimated value of the global respiratory equipment market segments (1995-2003)
Figure ES.3 Market segmentation of respiratory equipment (1998)
Figure 2.1 Estimated value of the global respiratory equipment market segments (1995-2003)
Figure 2.2 Relative values of the diagnostic and therapeutic equipment markets (1998)
Figure 2.3 Segmentation of the global respiratory market (1998 and 2003)
Figure 4.1 Healthcare expenditure in the US (1992-2003)
Figure 4.2 US population and predicted demographic development (1993-2020)*
Figure 4.3 Deaths due to bronchitis, emphysema and asthma in the US (1990-1996)*
Figure 4.4 Deaths due to respiratory disease by category in the US (1994-1996)
Figure 4.5 Patients with respiratory diseases discharged from short stay hospitals in the US (1993-1995)*
Figure 4.6 AIDS cases and deaths by year (1992-1997)
Figure 4.7 The US GDP (1992-1997)*
Figure 4.8 Healthcare expenditure in the US, as a percentage of GDP (1991-1995)
Figure 4.9 Segmentation of the US respiratory equipment market
Figure 4.10 Value of the US respiratory diagnostic equipment market (1992-2003)*
Figure 4.11 Value of the US respiratory therapeutic equipment market (1992-2003)
Figure 4.12 US imports and exports of respiratory therapeutic equipment (1994-1996)*
Figure 4.13 Main US trading partners (1993)
Figure 4.14 Main US trading partners (1996)
Figure 5.1 Healthcare expenditure in Japan (1990-1994)*
Figure 5.2 Japanese public and private sector healthcare expenditure (1992-2003)
Figure 5.3 Japan's population and predicted demographic development (1993-2020)*
Figure 5.4 Deaths due to bronchitis, emphysema and asthma in Japan (1989-1996)*
Figure 5.5 Deaths caused by bronchitis, emphysema and asthma in Japan (1993-1996)
Figure 5.6 Patients diagnosed with COPDs, sleep apnoea and asthma in Japan (1998)
Figure 5.7 Japan's GDP (1992-1997)*
Figure 5.8 Japan's healthcare expenditure, as a percentage of GDP (1991-1995)
Figure 5.9 Segmentation of the Japanese respiratory equipment market
Figure 5.10 Value of Japanese respiratory diagnostic equipment market (1992-2003)*
Figure 5.11 Value of Japanese respiratory therapeutic equipment market (1992-2003)*
Figure 5.12 Japan's imports and exports of respiratory therapeutic equipment (1994-1996)*
Figure 5.13 Japan's main trading partners (1993)
Figure 5.14 Japan's main trading partners (1996)
Figure 6.1 Healthcare expenditure in Germany (1990-1994)*
Figure 6.2 Healthcare expenditure in Germany's private and public sectors (1992-2003)
Figure 6.3 Germany's population and predicted demographic development (1993-2020)*
Figure 6.4 Deaths due to bronchitis, emphysema and asthma in Germany (1990-1993)*
Figure 6.5 German hospital discharges of patients diagnosed with bronchitis, emphysema and asthma (1993-1995)
Figure 6.6 Number of smokers in Germany (1992 and 1995)
Figure 6.7 Germany's GDP (1992-1997)*
Figure 6.8 Germany's healthcare expenditure, as a percentage of GDP (1991-1995)
Figure 6.9 Segmentation of the German respiratory equipment market
Figure 6.10 Value of Germany's respiratory diagnostic equipment market (1992-2003)*
Figure 6.11 Value of Germany's respiratory therapeutic equipment market (1992-2003)*
Figure 6.12 Germany's imports and exports of respiratory therapeutic equipment (1994-1996)*
Figure 6.13 Germany's main trading partners (1993)
Figure 6.14 Germany's main trading partners (1996)
Figure 7.1 Healthcare expenditure in France (1992-2003)
Figure 7.2 France's population and predicted demographic development (1993-2020)*
Figure 7.3 Deaths due to bronchitis, emphysema and asthma in France (1990-1993)*
Figure 7.4 France's GDP (1992-1997)*
Figure 7.5 France's healthcare expenditure, as a percentage of GDP (1991-1995)
Figure 7.6 Segmentation of the French respiratory equipment market
Figure 7.7 Value of France's respiratory diagnostic equipment market (1992-2003)*
Figure 7.8 Value of France's respiratory therapeutic equipment market (1992-2003)*
Figure 7.9 French imports and exports of respiratory therapeutic equipment (1994-1996)*
Figure 7.10 France's main trading partners (1993)
Figure 7.11 France's main trading partners (1996)
Figure 8.1 Healthcare expenditure in the UK (1992-2003)
Figure 8.2 The UK's population and predicted demographic development (1993-2020)*
Figure 8.3 Deaths due to bronchitis, emphysema and asthma in the UK (1990-1993) (incidence per 100,000)
Figure 8.4 Hospital admissions for respiratory disease in the UK (1991-1996)*
Figure 8.5 The UK's GDP (1992-1997)
Figure 8.6 The UK's healthcare expenditure, as a percentage of GDP (1991-1995)
Figure 8.7 The UK government's expenditure on the NHS (1991-2003)
Figure 8.8 Structure of the NHS in 1998
Figure 8.9 NHS structure proposed in the UK government's White Paper
Figure 8.10 Segmentation of the UK's respiratory equipment market
Figure 8.11 Value of the UK's respiratory diagnostic equipment market (1992-2003)*
Figure 8.12 Value of the UK's respiratory therapeutic equipment market (1992-2003)*
Figure 8.13 The UK's imports and exports of respiratory therapeutic equipment (1994-1996)*
Figure 8.14 The UK's main trading partners (1993)
Figure 8.15 The UK's main trading partners (1996)
Figure 9.1 Healthcare expenditure in Italy (1990-1994)*
Figure 9.2 Healthcare expenditure in Italy by sector (1992-2003)
Figure 9.3 Italy's population and predicted demographic development (1993-2020)*
Figure 9.4 Deaths due to bronchitis, emphysema and asthma in Italy (1989-1994)*
Figure 9.5 Deaths due to bronchitis, emphysema and asthma in Italy (1994)
Figure 9.6 Smoking status of the Italian population (1995)*
Figure 9.7 Italy's GDP (1992-1997), in US$ billion
Figure 9.8 Italy's healthcare expenditure, as a percentage of GDP (1991-1995)
Figure 9.9 Segmentation of the Italian respiratory equipment market
Figure 9.10 Value of Italy's respiratory diagnostic equipment market (1992-2003)*
Figure 9.11 Value of Italy's respiratory therapeutic equipment market (1992-2003)*
Figure 9.12 Italy's imports and exports of respiratory therapeutic equipment (1994-1996)*
Figure 9.13 Italy's main trading partners (1993)
Figure 9.14 Italy's main trading partners (1996)
Figure 10.1 Healthcare expenditure in Spain (1990-1994)*
Figure 10.2 Healthcare expenditure in Spain (1992-2003)
Figure 10.3 Spain's population and predicted demographic development (1993-2020)*
Figure 10.4 Deaths due to bronchitis, emphysema and asthma in Spain (1989-1994)*
Figure 10.5 Deaths due to bronchitis, emphysema and asthma in Spain (1994)
Figure 10.6 Discharges from hospitals of patients diagnosed with bronchitis, emphysema and asthma in Spain, by region (1994)
Figure 10.7 Spain's GDP (1992-1997), in US$ billion
Figure 10.8 Spain's healthcare expenditure, as a percentage of GDP (1991-1995)
Figure 10.9 Segmentation of the Spanish respiratory equipment market
Figure 10.10 Value of Spain's respiratory diagnostic equipment market (1992-2003)*
Figure 10.11 Value of Spain's respiratory therapeutic equipment market (1992-2003)*
Figure 10.12 Spain's imports and exports of respiratory therapeutic equipment (1994-1996)*
Figure 10.13 Spain's main trading partners (1993)
Figure 10.14 Spain's main trading partners (1996)
Figure 11.1 3M's sales (1993-1997), expressed in US$ million
Figure 11.2 Allegiance's net sales and net income (1993-1997), expressed in US$ million
Figure 11.3 Allegiance's R&D expenditure, as a percentage of net sales (1995-1997)
Figure 11.4 Aradigm's total revenue and net income (loss) (1993-1997), expressed in US$ million
Figure 11.5 Astra's total sales and net income (1993-1997), expressed in SKr million
Figure 11.6 Astra's regional results, as a percentage of net revenue (1995-1997)
Figure 11.7 Astra's R&D expenditure, as a percentage of total sales (1993-1997)
Figure 11.8 Boehringer Ingelheim's net sales and net income (1993-1996), expressed in US$ million
Figure 11.9 Boehringer Ingelheim's regional results, as a percentage of net revenue (1995-1996)
Figure 11.10 Boehringer Ingelheim's R&D expenditure, as a percentage of net sales (1993-1996)
Figure 11.11 Clement Clarke's turnover and operating profit (1993, 1995 and 1996)
Figure 11.12 Clement Clarke's regional turnover (1993, 1995 and 1996)
Figure 11.13 Dr�ger's net sales and net income (1993-1996), expressed in US$ million
Figure 11.14 Dr�ger's net regional sales (1993-1996)
Figure 11.15 Dura's net revenue and net income (1993-1997), expressed in US$ million
Figure 11.16 Glaxo Wellcome's sales and pre-tax profit (1995-1997), expressed in US$ million
Figure 11.17 Glaxo Wellcome's R&D expenditure as a percentage of sales (1995-1997), expressed in US$ million
Figure 11.18 Invacare's net sales, gross profit and net earnings (1993-1997), expressed in US$ million
Figure 11.19 Invacare's regional results, as a percentage of net revenue (1994-1996)
Figure 11.20 Invacare's R&D expenditure, as a percentage of net revenue (1993-1996)
Figure 11.21 Mallinckrodt's net sales and net earnings (1993-1997), expressed in US$ million
Figure 11.22 Mallinckrodt's regional results, as a percentage of gross sales (1995-1997)
Figure 11.23 Mallinckrodt's healthcare regional results, as a percentage of net sales
Figure 11.24 Mallinckrodt's R&D expenditure, as a percentage of net sales (1995-1997)
Figure 11.25 Micro Medical's sales (1993-1997), expressed in US$ million
Figure 11.26 Micro Medical's net regional sales* (1993-1997)
Figure 11.27 Novametrix's net sales and net income (1994-1997), expressed in US$ million
Figure 11.28 Novametrix's R&D expenditure, as a percentage of net sales (1996-1997)
Figure 11.29 ResMed's net revenue and net income (1993-1997), expressed in US$ million
Figure 11.30 ResMed's regional results, as a percentage of net revenue (1993-1997)
Figure 11.31 ResMed's R&D expenditure, as a percentage of net revenue (1993-1997)
Figure 11.32 Respironics' net sales and net income (1993-1997), expressed in US$ million
Figure 11.33 Respironics' net regional sales*, as a percentage of total net sales (1995-1997)
Figure 11.34 Respironics' R&D expenditure, as a percentage of net sales (1995-1997)
Figure 11.35 Siemens' net sales and net income (1993-1997), expressed in US$ million
Figure 11.36 Contribution of Siemens Medical System's sales to total net sales (1994 and 1997)
Figure 11.37 Siemens' net regional sales, as a percentage of total net sales (1993-1997)
Figure 11.38 Siemens' R&D expenditure, as a percentage of net sales (1993-1997)
Figure 11.39 SIMS' turnover and profit (1993-1997), expressed in US$ million
Figure 11.40 Smiths Industries' regional results, as a percentage of net revenue (1996-1997)
Figure 11.41 Sunrise Medical's net sales and net income (1993-1997), expressed in US$ million
Figure 11.42 Contribution of DeVilbiss sales to total net sales (1994 and 1997)
Figure 11.43 Sunrise Medical's net regional sales, as a percentage of total net sales (1993-1997)
Figure 11.44 Sunrise Medical's R&D expenditure, as a percentage of net sales (1993-1997)
Figure 11.45 Vital Signs' product line contribution to total net sales (1996-1997)
Figure 11.46 Vital Signs' net sales and net income (1993-1997), expressed in US$ million
Figure 11.47 Vital Signs' net regional sales, as a percentage of total net sales (1995-1997)
Figure 11.48 Vital Signs' R&D expenditure, as a percentage of net sales (1995-1997)
Figure 11.49 Vitalograph's sales (1993-1997), expressed in millions

EXECUTIVE SUMMARY
The global respiratory equipment market is divided into two broad segments, comprising diagnostic and therapeutic equipment. Differentiated in clinical terms, the segments are also largely separated in terms of the associated industries, with the majority of manufacturers active in either one or other of the segments.

This report concerns itself with the markets for the equipment used to diagnose and treat/alleviate chronic respiratory disorders. These can be divided into three areas: asthma, the chronic obstructive pulmonary diseases (COPDs) and sleep apnoea. It is these conditions which drive the respiratory diagnostic and therapeutic device industries. However, the industries are also influenced by a number of other direct and indirect factors, which are included in Table ES.1 below:

Table ES.1: Factors influencing the respiratory diagnostic and therapeutic device industries

Source: PJB Publications, Reports Division, 1998.

This report covers the markets for respiratory diagnostics and therapeutic equipment in the seven most important markets in the world. Table ES.2 shows the ranking of these markets in order of importance:

Table ES.2: The top seven world markets for respiratory equipment (1998)

Source: PJB Publications, Reports Division, 1998.

• Order this report.
• Request a catalogue.
• Home.

© PJB Publications Ltd. 2001
All rights reserved.